# A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors

Source: https://onco.cc/trials/nct07488676/  
OnCo record `nct07488676` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of ASP546C in gastric & gastro-oesophageal junction cancer and pancreatic ductal adenocarcinoma, run by Astellas Pharma Global Development, Inc., now recruiting.

## Summary

A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors is a phase 1/2 interventional study registered as NCT07488676 by Astellas Pharma Global Development, Inc., with 150 participants planned, started 2026-05-04 and due to reach its primary completion in 2029-07-31. Interventions recorded: ASP546C.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07488676
- Phase: 1/2
- Setting: A Phase 1b/2 Open-label Study to Assess the Safety and Efficacy of ASP546C in Participants With CLDN18.2-expressing Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma, Pancreatic Adenocarcinoma or Other Solid Tumor Types
- Sponsor: Astellas Pharma Global Development, Inc.
- Enrolled: 150

## Sources

- ClinicalTrials.gov NCT07488676: https://clinicaltrials.gov/study/NCT07488676

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- companies: [Astellas](https://onco.cc/companies/astellas/)

---
JSON: https://onco.cc/api/v1/entities/nct07488676.json